Don't miss

OmniBio Pharmaceutical, Inc. (OMBP)

By on March 20, 2013

omni_bioOmni Bio Pharmaceutical, Inc. (OTCBB: OMBP) is a clinical-stage biopharmaceutical company that has licensed potential new therapies currently in development for an existing FDA approved drug – Alpha-1 antitrypsin (AAT). Their strategy is to advance new therapies for AAT that we believe have the potential to move through clinical trials quickly, shepherd them through the FDA approval process and advance them through to commercialization. They intend to leverage clinical trials and sponsored research agreements with collaborations with existing AAT manufacturers for the development and commercialization of AAT in additional indications that potentially could exceed AAT’s current estimated market of $400 million. They plan to collaborate with companies that have the infrastructure, expertise and large scale marketing capability to properly handle late-stage clinical development and commercialization.

Company Data

Industry: BioTech

IR Contact: Robert Ogden CFO

Phone: (720) 488-4754

IR Email: bogden@omnibiopharma.com

Address: OmniBio Pharmaceutical, Inc.
5350 S. Roslyn Street, Suite 430
Greenwood Village, CO 80111

Fiscal Year End: December, 31st

Executives: Bruce Schneider, PH.D CEO, Charles Dinarello CSO, Robert Ogden CFO

Online Resources

Company Website:

Stock Information:

Company Fillings

Video Presentations

Watch this video to learn more about Omni Bio’s breakthrough research for plasma and synthetic Alpha-1 Antitrypsin (AAT).

Dr. Charles Dinarello discusses article he co-authored in Blood Magazine

You must be logged in to post a comment Login